A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (The DART-AD Trial)
Background: There have been increasing concerns regarding the safety and efficacy of neuroleptics in people with dementia, but there are very few long-term trials to inform clinical practice. The aim of this study was to determine the impact of long-term treatment with neuroleptic agents upon global...
Main Authors: | Ballard, C, Lana, M, Theodoulou, M, Douglas, S, McShane, R, Jacoby, R, Kossakowski, K, Yu, L, Juszczak, E |
---|---|
Formato: | Journal article |
Idioma: | English |
Publicado: |
2008
|
Títulos similares
-
A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (The DART-AD Trial)
por: Ballard, C, et al.
Publicado: (2008) -
A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial).
por: Ballard, C, et al.
Publicado: (2008) -
A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial).
por: Clive Ballard, et al.
Publicado: (2008-04-01) -
The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial.
por: Ballard, C, et al.
Publicado: (2009) -
A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cutoff is a predictor of clinical outcome.
por: Ballard, C, et al.
Publicado: (2004)